| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 21 | 2016 | 415 | 2.860 |
Why?
|
| RNA, Small Interfering | 17 | 2017 | 436 | 1.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2024 | 968 | 1.310 |
Why?
|
| RNA Interference | 5 | 2017 | 247 | 1.210 |
Why?
|
| Cell Proliferation | 12 | 2024 | 1455 | 1.190 |
Why?
|
| Cisplatin | 5 | 2016 | 98 | 1.070 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2026 | 13 | 0.960 |
Why?
|
| MicroRNAs | 2 | 2024 | 518 | 0.890 |
Why?
|
| Electrocardiography | 1 | 2026 | 185 | 0.890 |
Why?
|
| Antineoplastic Agents | 9 | 2016 | 1019 | 0.790 |
Why?
|
| Cell Movement | 4 | 2024 | 655 | 0.780 |
Why?
|
| Apoptosis | 12 | 2015 | 1568 | 0.750 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2014 | 12 | 0.740 |
Why?
|
| Cell Line, Tumor | 23 | 2024 | 2676 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2015 | 307 | 0.620 |
Why?
|
| Mice, Nude | 13 | 2015 | 408 | 0.560 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2015 | 347 | 0.550 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 51 | 0.510 |
Why?
|
| RNA-Binding Proteins | 3 | 2016 | 161 | 0.510 |
Why?
|
| Glioblastoma | 1 | 2017 | 74 | 0.490 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 44 | 0.480 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 140 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 63 | 0.450 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 1723 | 0.440 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2014 | 161 | 0.420 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 84 | 0.410 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 237 | 0.400 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2009 | 19 | 0.370 |
Why?
|
| Protein Isoforms | 1 | 2013 | 139 | 0.370 |
Why?
|
| Female | 24 | 2026 | 24698 | 0.370 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 652 | 0.360 |
Why?
|
| Taxoids | 2 | 2011 | 50 | 0.360 |
Why?
|
| Humans | 34 | 2026 | 43102 | 0.340 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 34 | 0.340 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 19 | 0.340 |
Why?
|
| Peroxiredoxins | 1 | 2009 | 11 | 0.310 |
Why?
|
| Genes, myc | 1 | 2009 | 31 | 0.300 |
Why?
|
| Down-Regulation | 3 | 2011 | 456 | 0.300 |
Why?
|
| Oxides | 2 | 2009 | 100 | 0.300 |
Why?
|
| Arsenicals | 2 | 2009 | 87 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 3 | 2024 | 139 | 0.290 |
Why?
|
| Piperazines | 1 | 2009 | 120 | 0.290 |
Why?
|
| Receptor, PAR-1 | 1 | 2008 | 8 | 0.290 |
Why?
|
| Pyrimidines | 1 | 2009 | 139 | 0.290 |
Why?
|
| Animals | 24 | 2017 | 16992 | 0.280 |
Why?
|
| Quinolinium Compounds | 2 | 1998 | 9 | 0.270 |
Why?
|
| Mice | 18 | 2013 | 6644 | 0.270 |
Why?
|
| Cell Division | 1 | 2008 | 311 | 0.270 |
Why?
|
| Melanoma | 1 | 2008 | 110 | 0.260 |
Why?
|
| Transcription Factors | 1 | 2011 | 735 | 0.240 |
Why?
|
| Disease Progression | 4 | 2024 | 667 | 0.240 |
Why?
|
| Equipment Design | 1 | 2026 | 145 | 0.230 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 116 | 0.220 |
Why?
|
| Blotting, Western | 5 | 2015 | 883 | 0.220 |
Why?
|
| Heart Rate | 1 | 2026 | 266 | 0.210 |
Why?
|
| Aged, 80 and over | 3 | 2026 | 2853 | 0.210 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 3 | 0.200 |
Why?
|
| Aged | 5 | 2026 | 8214 | 0.200 |
Why?
|
| Gene Silencing | 7 | 2013 | 154 | 0.200 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1271 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2024 | 561 | 0.180 |
Why?
|
| Reproducibility of Results | 1 | 2026 | 1081 | 0.180 |
Why?
|
| Autophagy | 2 | 2014 | 140 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2014 | 74 | 0.180 |
Why?
|
| Middle Aged | 6 | 2026 | 12222 | 0.180 |
Why?
|
| Carcinoma | 3 | 2013 | 108 | 0.170 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 83 | 0.170 |
Why?
|
| Liposomes | 3 | 2011 | 132 | 0.170 |
Why?
|
| Cell Survival | 5 | 2015 | 945 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 508 | 0.160 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2010 | 21 | 0.160 |
Why?
|
| Adult | 5 | 2026 | 13872 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 290 | 0.150 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 934 | 0.140 |
Why?
|
| Base Sequence | 3 | 2009 | 983 | 0.140 |
Why?
|
| Intercalating Agents | 1 | 1997 | 13 | 0.140 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 29 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2026 | 3156 | 0.130 |
Why?
|
| Phosphatidylcholines | 3 | 2011 | 35 | 0.130 |
Why?
|
| Young Adult | 2 | 2026 | 5080 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2011 | 84 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 34 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2009 | 218 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 82 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 174 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 704 | 0.120 |
Why?
|
| Erythropoietin | 1 | 2015 | 38 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2013 | 49 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 259 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 189 | 0.110 |
Why?
|
| DNA | 1 | 1997 | 592 | 0.110 |
Why?
|
| Adolescent | 1 | 2026 | 6081 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 273 | 0.100 |
Why?
|
| Diamines | 1 | 2013 | 8 | 0.100 |
Why?
|
| Receptor, EphA2 | 2 | 2010 | 6 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 35 | 0.100 |
Why?
|
| RNA Splicing | 1 | 2013 | 41 | 0.100 |
Why?
|
| Benzothiazoles | 1 | 2013 | 26 | 0.100 |
Why?
|
| Organic Chemicals | 1 | 2013 | 36 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 82 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 100 | 0.090 |
Why?
|
| Quinolines | 1 | 2013 | 78 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 701 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 310 | 0.090 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2011 | 3 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 3 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 526 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 11 | 0.090 |
Why?
|
| Microdissection | 1 | 2011 | 13 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 26 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 51 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2011 | 114 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 95 | 0.080 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 8 | 0.080 |
Why?
|
| Centrosome | 1 | 2010 | 30 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2010 | 74 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 99 | 0.080 |
Why?
|
| Silicon | 1 | 2010 | 17 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 83 | 0.080 |
Why?
|
| Anoikis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 10 | 0.080 |
Why?
|
| Adrenomedullin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Receptors, Peptide | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 220 | 0.080 |
Why?
|
| Signal Transduction | 7 | 2013 | 2157 | 0.080 |
Why?
|
| Cation Transport Proteins | 1 | 2009 | 35 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 25 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 294 | 0.070 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2008 | 42 | 0.070 |
Why?
|
| Transglutaminases | 1 | 2008 | 7 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2008 | 38 | 0.070 |
Why?
|
| Benzofurans | 1 | 2008 | 22 | 0.070 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2008 | 14 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 38 | 0.070 |
Why?
|
| Neuralgia | 1 | 2008 | 22 | 0.070 |
Why?
|
| Piperidines | 1 | 2008 | 83 | 0.070 |
Why?
|
| Analgesics | 1 | 2008 | 55 | 0.070 |
Why?
|
| Male | 3 | 2026 | 23409 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 458 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 166 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 277 | 0.070 |
Why?
|
| Norepinephrine | 3 | 2013 | 97 | 0.060 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 98 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2013 | 986 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 532 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 291 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 224 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2010 | 460 | 0.050 |
Why?
|
| HL-60 Cells | 2 | 2008 | 33 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2010 | 661 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 299 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2010 | 1596 | 0.050 |
Why?
|
| Discrimination Learning | 1 | 2003 | 38 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2010 | 134 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2011 | 536 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 512 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 462 | 0.040 |
Why?
|
| Hippocampus | 1 | 2003 | 594 | 0.040 |
Why?
|
| Protein Binding | 2 | 2015 | 1082 | 0.040 |
Why?
|
| Paclitaxel | 2 | 2010 | 64 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2014 | 1604 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 1998 | 7 | 0.030 |
Why?
|
| Etoposide | 1 | 1998 | 21 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1997 | 20 | 0.030 |
Why?
|
| Viscosity | 1 | 1997 | 46 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 21 | 0.030 |
Why?
|
| HT29 Cells | 1 | 1997 | 60 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 1998 | 154 | 0.030 |
Why?
|
| Hela Cells | 1 | 1997 | 376 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 186 | 0.030 |
Why?
|
| Receptors, Erythropoietin | 1 | 2015 | 6 | 0.030 |
Why?
|
| Models, Biological | 2 | 2010 | 712 | 0.030 |
Why?
|
| Protein Kinases | 2 | 2008 | 100 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 102 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 518 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
| Qa-SNARE Proteins | 1 | 2013 | 9 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 27 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2014 | 144 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2013 | 21 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 54 | 0.020 |
Why?
|
| Tyrosine | 1 | 2013 | 120 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 74 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2013 | 127 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 182 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 368 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 5 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 17 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 197 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 60 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 172 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 181 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 196 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 54 | 0.020 |
Why?
|
| Microvessels | 1 | 2011 | 31 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 160 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 70 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 72 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 95 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 209 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 403 | 0.020 |
Why?
|
| Restraint, Physical | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 88 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 144 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 38 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 39 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 20 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 76 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 139 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 532 | 0.020 |
Why?
|
| Epinephrine | 1 | 2010 | 36 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 278 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 638 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 187 | 0.020 |
Why?
|
| Glucose | 1 | 2011 | 244 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 43 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 34 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 223 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2009 | 37 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 164 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 876 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 458 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 62 | 0.020 |
Why?
|
| Spinal Nerves | 1 | 2008 | 5 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 37 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 12 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 346 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2008 | 65 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 82 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2008 | 18 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 123 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 127 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 26 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 129 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 3735 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 41 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 388 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 241 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 59 | 0.020 |
Why?
|
| Tretinoin | 1 | 2008 | 50 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 286 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 263 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 183 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 671 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1621 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 411 | 0.020 |
Why?
|
| Lung | 1 | 2009 | 492 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 329 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 437 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1124 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 638 | 0.010 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 13 | 0.010 |
Why?
|
| Receptors, Opioid, delta | 1 | 2003 | 23 | 0.010 |
Why?
|
| Space Perception | 1 | 2003 | 35 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 138 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 150 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 1177 | 0.010 |
Why?
|
| Rats, Long-Evans | 1 | 2003 | 108 | 0.010 |
Why?
|
| Maze Learning | 1 | 2003 | 113 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 455 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 386 | 0.010 |
Why?
|